WO2003084555A1 - Compositions destinees a l'inhibition de la fibrose - Google Patents

Compositions destinees a l'inhibition de la fibrose Download PDF

Info

Publication number
WO2003084555A1
WO2003084555A1 PCT/JP2003/004253 JP0304253W WO03084555A1 WO 2003084555 A1 WO2003084555 A1 WO 2003084555A1 JP 0304253 W JP0304253 W JP 0304253W WO 03084555 A1 WO03084555 A1 WO 03084555A1
Authority
WO
WIPO (PCT)
Prior art keywords
plant
genus
composition
anacardium
food
Prior art date
Application number
PCT/JP2003/004253
Other languages
English (en)
Japanese (ja)
Inventor
Toyoyuki Nishi
Setsuko Sekita
Hiroyuki Fuchino
Original Assignee
Nippon Shinyaku Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co., Ltd. filed Critical Nippon Shinyaku Co., Ltd.
Publication of WO2003084555A1 publication Critical patent/WO2003084555A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/22—Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/58—Meliaceae (Chinaberry or Mahogany family), e.g. Azadirachta (neem)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • composition for suppressing fibrosis Composition for suppressing fibrosis
  • the present invention relates to a fibrosis-suppressing activity of plants belonging to the genus Acacia, the genus Strifonodendron, the genus Anacardium, the genus O'cotea, and the genus Sedulella.
  • TGF-] 3 is an important site that regulates cell proliferation, differentiation, and repair and regeneration after tissue damage.
  • TGF-j3 promotes local infiltration of leukocytes and angiogenesis during repair of damaged tissues, and also produces extracellular matrix (laminin Bl, fibronectin, collagen, tenascin, and proteoglycan, etc.) And enhances deposition.
  • TGF-] 3 The production and deposition of extracellular matrix by TGF-] 3 consists of the following three mechanisms. First, TGF- promotes gene expression of extracellular matrix proteins and increases the synthesis and secretion of extracellular matrix proteins. Second, TGF- inhibits the synthesis of proteases that degrade the synthesized extracellular matrix, and at the same time increases the synthesis of protease inhibitors. Third, TGF-J3 increases integrin, a receptor for extracellular matrix, and promotes deposition of matrix around the cell.
  • TGF- ⁇ regulates the proliferation and differentiation of various cells, including fibroblasts, which are the main constituent cells of fibrous tissue, and produces and deposits extracellular matrix that is indispensable for wound treatment. It has a very important role for the living body to regulate. However, once the production or activity of excessive TGF-3 occurs and persists for some reason, fibrotic lesions such as glomerulonephritis, diabetic nephritis, cirrhosis, pulmonary fibrosis, and sclerotic lesions cause.
  • the present inventors have conducted intensive studies and, as a result, have found that a specific plant has a strong TGF—] 3-induced collagen production inhibitory action, and have completed the present invention.
  • the present invention provides a composition for inhibiting fibrosis, a composition for inhibiting TGF-] 3-induced collagen production, comprising at least one selected plant or a squeezed or extracted extract thereof, Composition, anti-cirrhosis composition, anti-pulmonary fibrosis composition, fibrosis-suppressing food, TGF- / 3-induced collagen production-suppressing food, anti-nephritis food, anti-cirrhosis food, anti-lung fiber Regarding food for illness.
  • examples of the plant belonging to the genus Acacia include Acacia concinna (Willd.) DC. Or Acacia 'leuco floea (Acacia leucophloea Willd.).
  • Japanese Unexamined Patent Publication No. Hei 5-2-271067 describes that it is possible to isolate a gallic ester having a fibrosis-suppressing action from Acutea qerrardii force, but Acacia concinna (Acutea concinna (Willd.) DC.) or Acacia leucophloea Willd.
  • Plants belonging to the genus Strifnodendron include stribodendron 'Noreno timama (Stryphnodendron barbatimam Mart.).
  • Examples of plants belonging to the genus Anacardium include Anacardium giganteum (Anacardium giganteura Loud). Plants belonging to the genus Ocotea include Ocotea opifera Mart.
  • plants belonging to the genus Sedurella include Cedrela odorata L ..
  • plants include above-ground parts such as leaves, stems, buds, flowers, woody parts, bark parts (bark) and underground parts such as roots and tubers, All parts such as seeds, fruits, and fats can be used.
  • the dried product obtained by drying the plant itself, its crushed product, or the juice obtained by squeezing it can be taken as it is, or together with drinks such as water, hot water, juice, milk, etc. It can be appropriately extracted and the extract can be taken.
  • a plant extract is obtained by extracting a plant with a solvent such as water (hot water) or alcohol by a conventional method, and concentrating it to dryness.
  • the extract can be taken or suspended or dissolved in beverages such as water, hot water, juice, milk and the like.
  • the extract may be purified by a conventional method, or may be spray-dried or freeze-dried. These may be used alone or as a mixture of two or more.
  • the dose of the plant or the amount of decoction varies depending on the sex, age, symptom, location, etc. of the recipient, but 1 to 100 g of a dried plant per adult per day is suitable. In the range of ⁇ 20 g.
  • the amount is preferably from 0.1 to 10 g, and preferably from 0.2 to 5 g, per adult per day. Both can be taken once a day or divided into 2 to 4 times a day.
  • the composition according to the present invention (hereinafter referred to as “the composition of the present invention”) is obtained by mixing a plant body of a plant, a squeezed extract, and an extract thereof as it is or in a physiologically acceptable non-toxic and inert carrier.
  • a physiologically acceptable non-toxic and inert carrier for example, it can be contained in the range of 0.01 to 99.5%, preferably in the range of 0.5 to 90%.
  • composition of the present invention can take any form such as powders, capsules, tablets, dragees, granules, acids, suspensions, solutions, syrups, and drops. It can also be in the form of an injection.
  • composition of the present invention has an anti-nephritis effect. Therefore, the composition of the present invention can be used as a medicament as a therapeutic agent for nephritis and a prophylactic agent for nephritis.
  • composition of the present invention may be added to foods, for example, general foods such as curry, pilaf, prepared foods, drinks and confections, or tablets. It can be used as a health food in the form of tablets and granules.
  • the dried bark of Acacia 'leucofuroa bark was dried, and 39.5 L of 99.5% methanol was added to 1185 g and extracted at room temperature for 3 days.
  • the extract was filtered with a filter paper, the residue was filtered off, an additional 1.9 L of 99.5% methanol was added to the residue, and the mixture was extracted again at room temperature for 3 days.
  • the extract was filtered with filter paper and combined with the first filtrate.
  • the extract was concentrated under reduced pressure to obtain 169.25 g of Acacia leucofuroa methanol extract.
  • TGF- ⁇ final concentration 3 ng Zm 1
  • [ 3 H] proline final concentration 5 ⁇ Ci / m 1
  • the cells were further cultured for 16 hours.
  • cultivation was performed by replacing with a serum-free medium containing only DMS II at the same concentration as in the case where the plant extract and TGF- ⁇ were added.
  • culture was performed with TGF-) 3 and the same serum-free medium supplemented with DMSO as described above.
  • the TGF-) 3-induced collagen production inhibitory activity rate was expressed as the [ 3 H] proline uptake inhibitory rate calculated from the following equation.
  • Table 1 shows the test results. Table 1. TGF-J3-induced collagen production inhibitory activity test results
  • composition of the present invention has an inhibitory effect on TGF-] 8-induced collagen production, it can be used for treatment, prevention and symptom improvement of nephritis, cirrhosis, pulmonary fibrosis, etc. caused by tissue fibrosis. I can do it.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medical Informatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

L'invention concerne des compositions utilisables dans le traitement, la prévention ou l'amélioration de maladies provoquées par la fibrose de tissus, notamment la néphrite. Elle concerne principalement des compositions destinées à inhiber la fibrose ou des aliments conduisant à inhiber la fibrose contenant au moins un élément sélectionné parmi les éléments comprenant Acacia concinna (Willd.) DC., Acacia leucophloea Willd., des plantes appartenant au genre Stryphnodendron, Anacardium, Ocotea et Cedrella, des jus pressés et des extraits de ces plantes.
PCT/JP2003/004253 2002-04-04 2003-04-03 Compositions destinees a l'inhibition de la fibrose WO2003084555A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002-102905 2002-04-04
JP2002102905A JP2005289813A (ja) 2002-04-04 2002-04-04 繊維化抑制用組成物

Publications (1)

Publication Number Publication Date
WO2003084555A1 true WO2003084555A1 (fr) 2003-10-16

Family

ID=28786278

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2003/004253 WO2003084555A1 (fr) 2002-04-04 2003-04-03 Compositions destinees a l'inhibition de la fibrose

Country Status (2)

Country Link
JP (1) JP2005289813A (fr)
WO (1) WO2003084555A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2717722A1 (fr) * 2011-06-07 2014-04-16 Dialpha Composition comprenant un extrait de pomme de cajou

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08119984A (ja) * 1994-08-31 1996-05-14 Nkk Corp ストレプトミセス属放線菌及びこの菌由来のＴＧＦ−β 阻害剤
WO1999018953A1 (fr) * 1997-10-16 1999-04-22 Children's Hospital Medical Center Of Northern California Flavonoides servant au traitement de la mucoviscidose

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08119984A (ja) * 1994-08-31 1996-05-14 Nkk Corp ストレプトミセス属放線菌及びこの菌由来のＴＧＦ−β 阻害剤
WO1999018953A1 (fr) * 1997-10-16 1999-04-22 Children's Hospital Medical Center Of Northern California Flavonoides servant au traitement de la mucoviscidose

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [online] GUPTA G.L. ET AL.: "Chemica examination of leaves of acacia concinna", XP002969961, Database accession no. 74:28841 *
DEVI S.R. ET AL.: "Tannins and related polyphenols from ten common acacia-Spp of India", BIORESOUR TECHNOL., vol. 36, no. 2, 1991, pages 189 - 192, XP002969957 *
DIRK SCHAEFER: "Catechol interferes with TGF-beta-induced elimination of transformed cells by normal cells: implication for the survival of transformed cells during carcinogenesis", INT. J. CANCER, vol. 60, no. 4, 1995, pages 520 - 526, XP002969959 *
JOAO C. PALLAZZO DE MELLO ET AL.: "A dimeric proanthocyanidin from stryphnodendron adstringens", PHYTOCHEMISTRY, vol. 51, no. 8, 1999, pages 1105 - 1107, XP004290939 *
MACKINNON S. ET AL.: "Antimalarial activity tropical meliaceae extracts and gedunin derivatives", J. NAT. PROD., vol. 60, no. 4, 1997, pages 336 - 341, XP002969955 *
NIWA YUKIE: "Oxidation injury and its defense system in vivo", RINSHO BYORI, vol. 47, no. 3, 1999, pages 189 - 209, XP002969963 *
PLANTA MEDICA, vol. 19, no. 1, 1971, pages 55 - 62 *
REGE N. ET AL.: "Hepatoprotective effect of dextro cyanidanol against carbon tetrachloride induced liver damage", INDIAN DRUGS, vol. 21, no. 1, 1984, pages 556 - 568, XP002969954 *
SIEGERS CLAUS PETER ET AL.: "Effects of dithiocard and (+)-catechin against carbon tetrachloride-alcohol-induced liver figros", AGENTS AND ACTIONS, vol. 12, no. 5, 1982, pages 743 - 748, XP002969958 *
TOSHIKAZU SEKINE ET AL.: "(+)-Acacialactam, a new seven-membere LACTAM from the seeds of acacia concinna", CHEM. PHARM. BULL., vol. 37, no. 11, 1989, pages 3164 - 3165, XP002969960 *
UNNIKIRSHNAN V.S. ET AL.: "Protective effect of D-(+)-catechin on liver in carbon tetrachloride treated rats", INDIAN J. CLINICAL BIOCHEMISTRY, vol. 4, no. 2, 1989, pages 133 - 140, XP002969962 *
YASUHIRO TEZUKA ET AL.: "Kinmoonsides A-C, three new cytotoxic saponins from the fruits of acacia concinna, a medicinal plant collected in myanmar", J. NAT. PROD., vol. 63, no. 12, 2000, pages 1658 - 1664, XP002969956 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2717722A1 (fr) * 2011-06-07 2014-04-16 Dialpha Composition comprenant un extrait de pomme de cajou

Also Published As

Publication number Publication date
JP2005289813A (ja) 2005-10-20

Similar Documents

Publication Publication Date Title
CN102686227B (zh) 一种使用麦麸提取物或由其分离得到的活性成分治疗肥胖症的组合物
KR101368293B1 (ko) 참다래 과실 발효물을 이용한 항염증제 조성물 및 피부 미백제 조성물
KR100587398B1 (ko) 항지방화 및 항비만 활성을 갖는 박과 식물 추출물 또는이로부터 분리한 정제물을 포함하는 조성물
KR102137136B1 (ko) 호박 가수분해 추출물, 구약감자 가수분해 추출물, 강황 추출물 및 카카오닙스 추출물을 포함하는 조성물
US20220354918A1 (en) Anti-obesity composition including geumhwagyu extract as active ingredient
WO2003084555A1 (fr) Compositions destinees a l'inhibition de la fibrose
KR101075554B1 (ko) 돌단풍 추출물 또는 이의 분획물을 유효성분으로 함유하는 폐경기 증후군 예방 및 치료용 조성물
KR20160060834A (ko) 식물 추출물을 포함하는 케피어 그레인 배지 조성물 및 그 배지 조성물에 의한 발효 배양물을 포함하는 피부 상태 개선용 조성물
JP2019052109A (ja) 筋形成促進用組成物
KR20150077794A (ko) 한약재 추출물을 유효성분으로 함유하는 항비만 조성물
KR20230036758A (ko) 수면유도 및 불면증 치료용 효소처리 초고압 혼합추출물
KR100798004B1 (ko) 항지방화 및 항비만 활성을 갖는 박과 식물 추출물로부터분리된 화합물을 포함하는 조성물
KR101399398B1 (ko) 액상발효법을 이용한 산마늘 발효물의 제조방법 및 산마늘 발효물을 포함하는 당뇨 또는 당뇨합병증 예방 또는 치료용 조성물
US20100183754A1 (en) Extract and compound for blood pressure regulation
KR101072904B1 (ko) 비만 억제용 조성물
KR101231583B1 (ko) 밀겨 추출물로부터 분리한 유효물질을 이용한 비만 개선제 조성물
KR101612386B1 (ko) 진귤 종자 가공물을 이용한 화장품 조성물
WO2019090977A1 (fr) Vin fonctionnel de fruit de topinambour et son procédé de préparation
KR101370679B1 (ko) 고상발효법을 이용한 산마늘 발효물의 제조방법 및 산마늘 발효물을 포함하는 당뇨 또는 당뇨합병증 예방 또는 치료용 조성물
JP5279163B2 (ja) 抗老化剤、血小板凝集抑制剤、抗酸化剤、抗アレルギー剤及び飲食品
KR20110080998A (ko) 블랙 큐란트 안토시아닌을 함유하는 피부 주름 개선 및 예방용 조성물
KR101649830B1 (ko) 방사무늬김 추출물을 함유하는 당뇨병의 예방 또는 치료용 조성물
JP2017206477A (ja) 筋形成促進用組成物
KR20230158688A (ko) 호박씨 성분을 포함하는 욕창 예방용 조성물 및 이를 포함하는 외용제
KR20230036756A (ko) 항산화 및 미백용 초고압 초음파 추출물

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP